Truvestments Capital LLC Takes $63,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Truvestments Capital LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 544 shares of the company’s stock, valued at approximately $63,000.

A number of other hedge funds have also made changes to their positions in NBIX. Plato Investment Management Ltd grew its stake in Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after buying an additional 10,548 shares during the last quarter. Swiss National Bank boosted its holdings in Neurocrine Biosciences by 1.4% in the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after acquiring an additional 4,100 shares during the last quarter. KBC Group NV boosted its holdings in Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock worth $2,186,000 after buying an additional 8,332 shares during the last quarter. Tidal Investments LLC boosted its holdings in Neurocrine Biosciences by 57.8% during the first quarter. Tidal Investments LLC now owns 9,542 shares of the company’s stock worth $1,316,000 after buying an additional 3,497 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth about $5,848,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of research analyst reports. Raymond James reaffirmed an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Jefferies Financial Group raised their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada dropped their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Finally, Barclays dropped their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Price Performance

NBIX opened at $126.59 on Thursday. The business has a fifty day simple moving average of $118.97 and a 200 day simple moving average of $131.71. The company has a market capitalization of $12.82 billion, a PE ratio of 33.94 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 1 year low of $110.81 and a 1 year high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.